Switch to:
Also traded in: Austria, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 2.94
VRTX's Cash-to-Debt is ranked lower than
68% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. VRTX: 2.94 )
Ranked among companies with meaningful Cash-to-Debt only.
VRTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.66  Med: 2.47 Max: N/A
Current: 2.94
Equity-to-Asset 0.51
VRTX's Equity-to-Asset is ranked lower than
68% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. VRTX: 0.51 )
Ranked among companies with meaningful Equity-to-Asset only.
VRTX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.02  Med: 0.51 Max: 0.95
Current: 0.51
-0.02
0.95
Interest Coverage 4.78
VRTX's Interest Coverage is ranked lower than
92% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. VRTX: 4.78 )
Ranked among companies with meaningful Interest Coverage only.
VRTX' s Interest Coverage Range Over the Past 10 Years
Min: 0.12  Med: 2.81 Max: 2.96
Current: 4.78
0.12
2.96
Piotroski F-Score: 8
Altman Z-Score: 13.26
Beneish M-Score: -2.76
WACC vs ROIC
13.83%
41.92%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 16.16
VRTX's Operating Margin % is ranked higher than
84% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. VRTX: 16.16 )
Ranked among companies with meaningful Operating Margin % only.
VRTX' s Operating Margin % Range Over the Past 10 Years
Min: -602.63  Med: -84.82 Max: 8.07
Current: 16.16
-602.63
8.07
Net Margin % 12.19
VRTX's Net Margin % is ranked higher than
80% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. VRTX: 12.19 )
Ranked among companies with meaningful Net Margin % only.
VRTX' s Net Margin % Range Over the Past 10 Years
Min: -630.27  Med: -90.57 Max: 2.1
Current: 12.19
-630.27
2.1
ROE % 20.49
VRTX's ROE % is ranked higher than
91% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. VRTX: 20.49 )
Ranked among companies with meaningful ROE % only.
VRTX' s ROE % Range Over the Past 10 Years
Min: -180.27  Med: -57.99 Max: 4.58
Current: 20.49
-180.27
4.58
ROA % 9.09
VRTX's ROA % is ranked higher than
88% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. VRTX: 9.09 )
Ranked among companies with meaningful ROA % only.
VRTX' s ROA % Range Over the Past 10 Years
Min: -58.14  Med: -27.38 Max: 1.51
Current: 9.09
-58.14
1.51
ROC (Joel Greenblatt) % 48.86
VRTX's ROC (Joel Greenblatt) % is ranked higher than
89% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. VRTX: 48.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
VRTX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1092.55  Med: -102.98 Max: 110.77
Current: 48.86
-1092.55
110.77
3-Year Revenue Growth Rate 8.90
VRTX's 3-Year Revenue Growth Rate is ranked higher than
59% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. VRTX: 8.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
VRTX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -32.5  Med: 10.95 Max: 129.4
Current: 8.9
-32.5
129.4
3-Year EPS without NRI Growth Rate -41.00
VRTX's 3-Year EPS without NRI Growth Rate is ranked lower than
86% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. VRTX: -41.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
VRTX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -41  Med: 10.3 Max: 94.9
Current: -41
-41
94.9
» VRTX's 30-Y Financials

Financials (Next Earnings Date: 2017-10-25 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

VRTX Guru Trades in Q3 2016

Jeremy Grantham 50,300 sh (New)
John Burbank 2,830 sh (New)
Manning & Napier Advisors, Inc 142,540 sh (+12.25%)
Pioneer Investments 1,231,092 sh (+10.73%)
Ken Fisher 5,168 sh (+1.10%)
Vanguard Health Care Fund 12,914,741 sh (unchged)
Jeremy Grantham 100,000 sh (unchged)
David Carlson 270,000 sh (unchged)
George Soros Sold Out
Jim Simons Sold Out
Joel Greenblatt 66,716 sh (-38.60%)
Eaton Vance Worldwide Health Sciences Fund 269,807 sh (-48.91%)
» More
Q4 2016

VRTX Guru Trades in Q4 2016

Steven Cohen 887,000 sh (New)
Paul Tudor Jones 9,611 sh (New)
Manning & Napier Advisors, Inc 2,126,020 sh (+1391.53%)
Jeremy Grantham 100,000 sh (+98.81%)
Vanguard Health Care Fund 13,230,341 sh (+2.44%)
Ken Fisher 5,168 sh (unchged)
Jeremy Grantham 100,000 sh (unchged)
David Carlson 270,000 sh (unchged)
Joel Greenblatt Sold Out
John Burbank Sold Out
Pioneer Investments 1,226,158 sh (-0.40%)
Eaton Vance Worldwide Health Sciences Fund 226,707 sh (-15.97%)
» More
Q1 2017

VRTX Guru Trades in Q1 2017

George Soros 3,600 sh (New)
Jim Simons 40,117 sh (New)
Pioneer Investments 1,518,822 sh (+23.87%)
Ken Fisher 5,213 sh (+0.87%)
David Carlson 270,000 sh (unchged)
Jeremy Grantham Sold Out
Paul Tudor Jones Sold Out
Vanguard Health Care Fund 13,014,973 sh (-1.63%)
Manning & Napier Advisors, Inc 1,764,419 sh (-17.01%)
Steven Cohen 271,663 sh (-69.37%)
Eaton Vance Worldwide Health Sciences Fund 180,739 sh (-20.28%)
» More
Q2 2017

VRTX Guru Trades in Q2 2017

Ray Dalio 18,673 sh (New)
Joel Greenblatt 182,515 sh (New)
Ken Fisher 5,946 sh (+14.06%)
Eaton Vance Worldwide Health Sciences Fund 180,739 sh (unchged)
George Soros Sold Out
Manning & Napier Advisors, Inc 1,631,126 sh (-7.55%)
Vanguard Health Care Fund 11,626,983 sh (-10.66%)
Pioneer Investments 1,326,757 sh (-12.65%)
David Carlson 230,000 sh (-14.81%)
Jim Simons 21,700 sh (-45.91%)
Steven Cohen 11,141 sh (-95.90%)
» More
» Details

Insider Trades

Latest Guru Trades with VRTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2017-06-30 Reduce -10.66%0.34%$107.45 - $135.53 $ 148.1323%11,626,983
Joel Greenblatt 2017-06-30 New Buy0.33%$107.45 - $135.53 $ 148.1323%182,515
Ken Fisher 2017-06-30 Add 14.06%$107.45 - $135.53 $ 148.1323%5,946
George Soros 2017-06-30 Sold Out 0.01%$107.45 - $135.53 $ 148.1323%0
Vanguard Health Care Fund 2017-03-31 Reduce -1.63%0.04%$74.89 - $109.35 $ 148.1368%13,014,973
Ken Fisher 2017-03-31 Add 0.87%$74.89 - $109.35 $ 148.1368%5,213
George Soros 2017-03-31 New Buy0.01%$74.89 - $109.35 $ 148.1368%3,600
Vanguard Health Care Fund 2016-12-31 Add 2.44%0.06%$72.02 - $95.36 $ 148.1382%13,230,341
Joel Greenblatt 2016-12-31 Sold Out 0.08%$72.02 - $95.36 $ 148.1382%0
Joel Greenblatt 2016-09-30 Reduce -38.60%0.04%$85 - $102.83 $ 148.1357%66,716
Ken Fisher 2016-09-30 Add 1.10%$85 - $102.83 $ 148.1357%5,168
George Soros 2016-09-30 Sold Out 0.02%$85 - $102.83 $ 148.1357%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ALXN, NAS:INCY, NAS:REGN, NAS:BIIB, NAS:BMRN, NAS:EXEL, NAS:ALNY, NAS:KITE, NAS:SGEN, NAS:TSRO, NAS:BIVV, NAS:IONS, NAS:UTHR, NAS:NBIX, NAS:TECH, NAS:BLUE, NAS:ACAD, NAS:CLVS, NAS:PTLA, NAS:SAGE » details
Traded in other countries:VRTX.Austria, VX1.Germany, VRTX.Mexico, VRTX.Switzerland, 0QZU.UK,
Headquarter Location:USA
Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets.

Vertex Pharmaceuticals discovers and develops small-molecule drugs for the treatment of serious diseases. The firm's key drugs are Kalydeco and Orkambi for cystic fibrosis and has also several mid- and late-stage products targeting this market. Vertex successfully developed and commercialized two HIV protease inhibitors, which were outlicensed to GlaxoSmithKline. Vertex's pipeline includes therapies for the treatment of cancer, pain, inflammatory diseases, and influenza.

Top Ranked Articles about Vertex Pharmaceuticals Inc

Vanguard Sells Medtronic, Cigna in 2nd Quarter Largest sales of the most recent quarter
Vanguard Health Care Fund (Trades, Portfolio) owns a portfolio composed of 74 stocks with a total value of $46.532 billion. During the second quarter the guru sold shares in the following stocks: Read more...
Weekly CFO Sells Highlight Recent sales from company chief financial officers
According to GuruFocus Insider Data, the recent CFO sells were: Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) and Johnson & Johnson (NYSE:JNJ). Read more...
Vertex Energy, Inc. to Release Second Quarter 2017 Financial Results on August 8, 2017
Why the Latest Vertex Pharmaceutical Data Is so Important The stock just ran more than 20% on a single development
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is one of the biotechnology space's biggest winners this week. The company is currently trading in and around all-time highs of $160 a share, having gained more than 20% in value alone over the last couple of days. For a development stage, small-cap biotechnology stock, 20% is all in a day's work. Read more...
Spiros Segalas Gains 5 New Holdings in 2nd Quarter Guru invests in technology and pharmaceutical companies
Spiros Segalas (Trades, Portfolio)’ Harbor Capital Appreciation Fund gained five new holdings in the second quarter. They are Activision Blizzard Inc. (NASDAQ:ATVI), Crown Castle International Corp. (NYSE:CCI), Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) and Snap Inc. (NYSE:SNAP). Read more...
Weekly CFO Sells Highlight Insiders sell Vertex, Salesforce, Amphenol
According to GuruFocus Insider Data, the recent chief financial officer sells were Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), Salesforce.com Inc. (NYSE:CRM) and Amphenol Corp. (NYSE:APH). Read more...
Galapagos NV Tests Cystic Fibrosis Treatment on First Patient The study's results will be published later this year
Galapagos NV (NASDAQ:GLPG), the Belgian clinical stage biotechnology company that collaborated with AbbVie Inc. (NYSE:ABBV) on a treatment for patients with cystic fibrosis, announced Feb. 1 that the first patient received doses during the Phase 2 clinical trial, called Albatross. The study will enroll up to 35 people. Read more...
Galapagos NV Announces Results From Cystic Fibrosis Treatment Study Researchers observed a decline in sweat chloride concentration
Galapagos NV (NASDAQ:GLPG), the Belgian clinical-stage biotechnology company that collaborated with AbbVie Inc. (NYSE:ABBV) on a treatment for patients affected with cystic fibrosis, announced last week the “topline results from its SAPHIRA 1 Phase 2 study in cystic fibrosis patients with potentiator GLPG1837.” Read more...
Piotroski F-Score in the Real World How has the F-Score fared in a real investing portfolio?
Two years ago I started a portfolio monitoring the performance of a portfolio constructed by using the Piotroski F-Score. Read more...
Testing of Treatment for Cystic Fibrosis Patients Begins Results of study will be released in the 2nd quarter of 2017
Galapagos NV (NASDAQ:GLPG), the Belgian clinical-stage biotechnology company that collaborates with AbbVie Inc. (NYSE:ABBV) on a treatment for patients affected with cystic fibrosis, announced Nov. 28 through Globe Newswire that it has started “a randomized, double-blind, placebo-controlled, single-center phase 1 study in at least 64 healthy Dutch volunteers with GLPG2737.” Read more...

Ratios

vs
industry
vs
history
PE Ratio 143.82
VRTX's PE Ratio is ranked lower than
93% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. VRTX: 143.82 )
Ranked among companies with meaningful PE Ratio only.
VRTX' s PE Ratio Range Over the Past 10 Years
Min: 25.82  Med: 95.54 Max: 560.57
Current: 143.82
25.82
560.57
Forward PE Ratio 88.50
VRTX's Forward PE Ratio is ranked lower than
92% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 21.98 vs. VRTX: 88.50 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 143.82
VRTX's PE Ratio without NRI is ranked lower than
93% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 31.31 vs. VRTX: 143.82 )
Ranked among companies with meaningful PE Ratio without NRI only.
VRTX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 25.82  Med: 126.86 Max: 560.57
Current: 143.82
25.82
560.57
Price-to-Owner-Earnings 115.10
VRTX's Price-to-Owner-Earnings is ranked lower than
94% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 34.46 vs. VRTX: 115.10 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
VRTX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 21.57  Med: 101.78 Max: 415.71
Current: 115.1
21.57
415.71
PB Ratio 22.07
VRTX's PB Ratio is ranked lower than
94% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. VRTX: 22.07 )
Ranked among companies with meaningful PB Ratio only.
VRTX' s PB Ratio Range Over the Past 10 Years
Min: 5.78  Med: 13.78 Max: 37.6
Current: 22.07
5.78
37.6
PS Ratio 17.23
VRTX's PS Ratio is ranked lower than
57% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. VRTX: 17.23 )
Ranked among companies with meaningful PS Ratio only.
VRTX' s PS Ratio Range Over the Past 10 Years
Min: 4.47  Med: 18.79 Max: 79.6
Current: 17.23
4.47
79.6
Price-to-Free-Cash-Flow 61.31
VRTX's Price-to-Free-Cash-Flow is ranked lower than
83% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. VRTX: 61.31 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
VRTX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.88  Med: 63.97 Max: 1635
Current: 61.31
12.88
1635
Price-to-Operating-Cash-Flow 55.94
VRTX's Price-to-Operating-Cash-Flow is ranked lower than
82% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. VRTX: 55.94 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
VRTX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 11.94  Med: 56.31 Max: 242.49
Current: 55.94
11.94
242.49
EV-to-EBIT 105.79
VRTX's EV-to-EBIT is ranked lower than
92% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. VRTX: 105.79 )
Ranked among companies with meaningful EV-to-EBIT only.
VRTX' s EV-to-EBIT Range Over the Past 10 Years
Min: -277.8  Med: -11.6 Max: 2137.9
Current: 105.79
-277.8
2137.9
EV-to-EBITDA 90.15
VRTX's EV-to-EBITDA is ranked lower than
91% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. VRTX: 90.15 )
Ranked among companies with meaningful EV-to-EBITDA only.
VRTX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1067.2  Med: -12.2 Max: 297.8
Current: 90.15
-1067.2
297.8
Current Ratio 3.49
VRTX's Current Ratio is ranked lower than
52% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. VRTX: 3.49 )
Ranked among companies with meaningful Current Ratio only.
VRTX' s Current Ratio Range Over the Past 10 Years
Min: 1.14  Med: 4.6 Max: 30.95
Current: 3.49
1.14
30.95
Quick Ratio 3.34
VRTX's Quick Ratio is ranked lower than
51% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. VRTX: 3.34 )
Ranked among companies with meaningful Quick Ratio only.
VRTX' s Quick Ratio Range Over the Past 10 Years
Min: 1.14  Med: 4.6 Max: 30.95
Current: 3.34
1.14
30.95
Days Inventory 122.41
VRTX's Days Inventory is ranked higher than
51% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. VRTX: 122.41 )
Ranked among companies with meaningful Days Inventory only.
VRTX' s Days Inventory Range Over the Past 10 Years
Min: 62.49  Med: 122.98 Max: 254.87
Current: 122.41
62.49
254.87
Days Sales Outstanding 42.46
VRTX's Days Sales Outstanding is ranked higher than
73% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. VRTX: 42.46 )
Ranked among companies with meaningful Days Sales Outstanding only.
VRTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 25.75  Med: 45.26 Max: 61.46
Current: 42.46
25.75
61.46
Days Payable 119.09
VRTX's Days Payable is ranked higher than
72% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. VRTX: 119.09 )
Ranked among companies with meaningful Days Payable only.
VRTX' s Days Payable Range Over the Past 10 Years
Min: 106.57  Med: 382.26 Max: 1204.41
Current: 119.09
106.57
1204.41

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.00
VRTX's 3-Year Average Share Buyback Ratio is ranked higher than
86% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. VRTX: -2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
VRTX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -23.2  Med: -12.35 Max: -2
Current: -2
-23.2
-2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 673.31
VRTX's Price-to-Net-Cash is ranked lower than
100% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. VRTX: 673.31 )
Ranked among companies with meaningful Price-to-Net-Cash only.
VRTX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.55  Med: 18.85 Max: 578.36
Current: 673.31
3.55
578.36
Price-to-Net-Current-Asset-Value 65.25
VRTX's Price-to-Net-Current-Asset-Value is ranked lower than
97% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. VRTX: 65.25 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
VRTX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.16  Med: 7.42 Max: 1835.5
Current: 65.25
2.16
1835.5
Price-to-Tangible-Book 27.60
VRTX's Price-to-Tangible-Book is ranked lower than
94% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. VRTX: 27.60 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
VRTX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.88  Med: 8.29 Max: 120.7
Current: 27.6
1.88
120.7
Price-to-Intrinsic-Value-Projected-FCF 23.07
VRTX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
92% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. VRTX: 23.07 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
VRTX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 19.82  Med: 55.21 Max: 819.67
Current: 23.07
19.82
819.67
Price-to-Median-PS-Value 0.92
VRTX's Price-to-Median-PS-Value is ranked higher than
61% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. VRTX: 0.92 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
VRTX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.27  Med: 1.04 Max: 3.98
Current: 0.92
0.27
3.98
Price-to-Graham-Number 13.28
VRTX's Price-to-Graham-Number is ranked lower than
95% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. VRTX: 13.28 )
Ranked among companies with meaningful Price-to-Graham-Number only.
VRTX' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 2.35  Med: 11.41 Max: 40.01
Current: 13.28
2.35
40.01
Earnings Yield (Greenblatt) % 0.95
VRTX's Earnings Yield (Greenblatt) % is ranked higher than
75% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. VRTX: 0.95 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
VRTX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -26.6  Med: -3.9 Max: 5.4
Current: 0.95
-26.6
5.4

More Statistics

Revenue (TTM) (Mil) $2,131.34
EPS (TTM) $ 1.03
Beta1.95
Short Percentage of Float1.47%
52-Week Range $71.46 - 167.86
Shares Outstanding (Mil)252.12

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 2,188 2,755 3,479
EPS ($) 1.46 3.21 5.09
EPS without NRI ($) 1.46 3.21 5.09
EPS Growth Rate
(Future 3Y To 5Y Estimate)
74.98%
Dividends per Share ($)
» More Articles for VRTX

Headlines

Articles On GuruFocus.com
Vanguard Sells Medtronic, Cigna in 2nd Quarter Aug 17 2017 
Weekly CFO Sells Highlight Jul 30 2017 
Vertex Energy, Inc. to Release Second Quarter 2017 Financial Results on August 8, 2017 Jul 25 2017 
The Real Reason Why the Latest Vertex Pharmaceutical Data Is so Important Jul 20 2017 
Spiros Segalas Gains 5 New Holdings in 2nd Quarter Jul 10 2017 
Weekly CFO Sells Highlight Jun 08 2017 
Eaton Vance Worldwide Health Sciences Fund 1st Quarter Investment Report May 02 2017 
Galapagos NV Tests Cystic Fibrosis Treatment on First Patient Feb 03 2017 
Galapagos NV Announces Results From Cystic Fibrosis Treatment Study Dec 27 2016 
Piotroski F-Score in the Real World Dec 19 2016 

More From Other Websites
The 3 Best Stocks in Healthcare Aug 17 2017
3 Stocks That Could Put Alibaba's Returns to Shame Aug 16 2017
ETFs with exposure to Vertex Pharmaceuticals, Inc. : August 15, 2017 Aug 15 2017
Why Gilead Sciences Might Not Make an Oncology Acquisition Aug 15 2017
Why Vertex Pharmaceuticals Incorporated (VRTX) Stock Isn’t Worth the Risk Aug 14 2017
CD 2016-CD1 Mortgage Trust -- Moody's Affirms Eight Classes of CD 2016-CD1 Aug 11 2017
See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc. Aug 11 2017
IHS Markit Score downgrades Vertex Pharmaceuticals Inc to 64 out of 100, ranking positively in only... Aug 10 2017
Why Vertex Pharmaceuticals Incorporated (VRTX) Will Keep Rolling Higher Aug 08 2017
For Vertex Pharmaceuticals, Can One Billion-Dollar Breakthrough Beget Another? Aug 08 2017
Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals: Which Company Reported Better Earnings Aug 04 2017
Why Vertex Pharmaceuticals Skyrocketed 17.8% in July Aug 03 2017
Should You Buy Vertex Pharmaceuticals Incorporated (VRTX) Stock? 3 Pros, 3 Cons Aug 03 2017
Corporate News Blog - Vertex Pharma Announces Approval from the FDA For KALYDECO in More Than 600... Aug 03 2017
Vertex’s latest FDA nod could boost sales by $150M: analyst Aug 02 2017
Biotech Stock Roundup: Q2 Earnings from Gilead, CELG & More, Dynavax Up on Panel Vote Aug 02 2017
Vertex Pharmaceuticals, Inc. :VRTX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 1, 2017 Aug 01 2017
FDA Approves KALYDECO® (ivacaftor) for More Than 600 People Ages 2 and Older With Cystic Fibrosis... Aug 01 2017
Vertex Pharmaceuticals Incorporated Chugs Along Jul 28 2017
Vertex Pharmaceuticals: Looking East, West and to the Quants Jul 27 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}